PDCD1 and melanoma: Immune check-point therapy based on cytotoxic T lymphocyte-associated antigen 4 (CTLA4), programmed death-1 (PD-1), and programmed death ligand-1 (PD-L1) inhibitors has a good effect in non–small-cell lung carcinoma and melanoma (90, 91).